Northcoast Asset Management buys $52,824,378 stake in Gilead Sciences (GILD)

Gilead Sciences (GILD) : Northcoast Asset Management scooped up 75,376 additional shares in Gilead Sciences during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 663,123 shares of Gilead Sciences which is valued at $52,824,378.Gilead Sciences makes up approximately 4.30% of Northcoast Asset Management’s portfolio.

Other Hedge Funds, Including , Meiji Yasuda Life Insurance Co reduced its stake in GILD by selling 1,360 shares or 2.71% in the most recent quarter. The Hedge Fund company now holds 48,748 shares of GILD which is valued at $3,883,266. Gilead Sciences makes up approx 0.60% of Meiji Yasuda Life Insurance Co’s portfolio.Progressive Investment Management Corp boosted its stake in GILD in the latest quarter, The investment management firm added 202 additional shares and now holds a total of 4,503 shares of Gilead Sciences which is valued at $358,709. Gilead Sciences makes up approx 0.33% of Progressive Investment Management Corp’s portfolio.Tocqueville Asset Management reduced its stake in GILD by selling 21,047 shares or 8.45% in the most recent quarter. The Hedge Fund company now holds 227,991 shares of GILD which is valued at $18,118,445. Gilead Sciences makes up approx 0.23% of Tocqueville Asset Management’s portfolio.

Gilead Sciences closed down -0.96 points or -1.22% at $77.42 with 1,24,03,880 shares getting traded on Thursday. Post opening the session at $78.43, the shares hit an intraday low of $76.94 and an intraday high of $78.455 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.

On the company’s financial health, Gilead Sciences reported $3.08 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on Jul 25, 2016. Analyst had a consensus of $3.01. The company had revenue of $7776.00 million for the quarter, compared to analysts expectations of $7795.08 million. The company’s revenue was down -5.7 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $3.15 EPS.

Investors should note that on Jul 25, 2016, Gilead Sciences announced a cash dividend of $0.4700. The company’s management has announced Sep 14, 2016 as the ex-dividend date and fixed the record date on Sep 16, 2016. The payable date has been fixed on Sep 29, 2016.

Many Wall Street Analysts have commented on Gilead Sciences. Gilead Sciences was Upgraded by Jefferies to ” Buy” on Sep 6, 2016. Gilead Sciences was Downgraded by Argus to ” Hold” on Jul 29, 2016. Shares were Reiterated by RBC Capital Mkts on Jul 26, 2016 to “Outperform” and Lowered the Price Target to $ 105 from a previous price target of $120 .

Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Company’s primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Company’s HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Company’s oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.

Leave a Reply

Gilead Sciences - Is it time to Sell?

Top Brokerage Firms are advising their investors on Gilead Sciences. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.